NLRP3 and arthritic joint disease: AB4 treatment inhibits spinal GSK‐3β activity, enhances Nrf2/GPX4 antioxidant response, reduces Drp1‐mediated mitochondrial ROS production, suppresses NLRP3 inflammasome activation and alleviates arthritis pain (Figure 8).